Switching from NovoLog to Fiasp: Direct 1:1 Conversion
When transitioning a patient from NovoLog (insulin aspart) to Fiasp (faster-acting insulin aspart), start with a direct unit-to-unit conversion using the same insulin-to-carbohydrate ratio of 1 unit per 2 grams of carbohydrate. 1
Initial Conversion Approach
The FDA-approved prescribing information for Fiasp explicitly states that "if converting from another mealtime insulin to FIASP, the initial change can be done on a unit-to-unit basis" 1. This means:
- Maintain the same carbohydrate ratio: Continue using 1 unit for every 2 grams of carbohydrate
- Keep the same correction factor initially
- No dose reduction required at the time of switch
Both insulins are formulations of insulin aspart with the same total insulin content (100 units/mL), making the 1:1 conversion straightforward and safe.
Critical Timing Adjustment
The key difference requiring patient education is injection timing relative to meals:
- NovoLog: Inject 5-10 minutes before the meal 2
- Fiasp: Inject at the start of the meal OR up to 20 minutes after starting the meal 1
This flexibility with Fiasp is due to its faster onset of action (approximately 2.5 times faster initial glucose-lowering effect within 30 minutes) 3.
Monitoring Requirements During Transition
Increase blood glucose monitoring frequency during the switch 1. The FDA label specifically warns that changes in insulin regimen may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Monitor:
- Pre-meal glucose levels
- 1-2 hour postprandial glucose (Fiasp shows superior control at 30 minutes, 1 hour, and 2 hours post-meal compared to standard insulin aspart) 4, 5
- Overnight glucose if using continuous glucose monitoring
When Dose Adjustments May Be Needed
While the initial conversion is 1:1, dose adjustments may be necessary after the switch based on 1:
- Changes in physical activity patterns
- Meal pattern variations (macronutrient content or timing)
- Renal or hepatic function changes
- Concurrent illness
The 2025 ADA Standards recommend reassessing and modifying insulin regimens regularly every 3-6 months to avoid therapeutic inertia 6.
Special Considerations for Insulin Pump Users
If the patient uses an insulin pump rather than injections, the conversion remains unit-to-unit, but all pump settings should be reviewed and potentially adjusted 7, 8. Fiasp in pumps requires:
- Reservoir changes at least every 6 days (or PumpCart every 4 days) 1
- Possible adjustment of bolus timing and extended bolus settings
- Enhanced monitoring with CGM during the first weeks 7
Common Pitfalls to Avoid
Do not arbitrarily reduce the insulin dose when switching—this is unnecessary and may lead to hyperglycemia. The evidence shows that faster aspart provides improved postprandial control without increasing hypoglycemia risk when dosed appropriately 4, 9.
Do not mix Fiasp with other insulins in syringes or pump reservoirs 1. Unlike some insulin formulations, Fiasp should not be combined with basal insulins.
Watch for injection site reactions, which occur more frequently with Fiasp than standard insulin aspart 4. Rotate injection sites within the same region to minimize lipodystrophy and localized cutaneous amyloidosis 1.
Expected Clinical Benefits
Patients should understand that while overall A1C improvements may be modest, Fiasp provides superior postprandial glucose control, particularly in the first 1-2 hours after meals 4, 5, 3. This translates to reduced glucose excursions and improved time-in-range when pump settings are optimized 4.